Girard Partners’s AMAG Pharmaceuticals AMAG Stock Holding History

Girard Partners’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-100	Closed	-$2K	–	918
2018 Q3	$2K	Buy	+100	New	+$2.28K	﹤0.01%	908

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Girard Partners's AMAG Position: Q4 2018 in Review

Girard Partners sold out of AMAG Pharmaceuticals (AMAG) in Q4 2018, closing a stake of 100 shares — an estimated $2K sold.

Girard Partners first reported a position in AMAG in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 190 funds tracked by Wall St. Rank hold AMAG as of Q4 2018.

Girard Partners reported no remaining AMAG Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Girard Partners sold 100 AMAG Pharmaceuticals shares in Q4 2018, an estimated $2K.
Girard Partners first reported a position in AMAG Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Girard Partners's AMAG Pharmaceuticals position peaked at $2K in Q3 2018.
190 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.